Filter Results
Glasdegib + LDAC Improves Survival in Newly Diagnosed AML
In patients with newly diagnosed acute myeloid leukemia (AML), one cycle of therapy with glasdegib plus low-dose cytarabine (LDAC) improved overall survival (OS) associated with various blood count thresholds.
Integrating Palliative Care Into AML Treatment Improves Quality of Life
An integrated palliative and oncology care model for acute myeloid leukemia (AML) patients undergoing intensive chemotherapy resulted in substantial improvements in patients’ quality of life (QOL), psychological distress, and end-of-life (EOL) care.